437 related articles for article (PubMed ID: 17398202)
1. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
4. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
5. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin-system blockade in the prevention of diabetes.
Ostergren J
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
[TBL] [Abstract][Full Text] [Related]
8. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Abuissa H; Jones PG; Marso SP; O'Keefe JH
J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
Anand K; Mooss AN; Hee TT; Mohiuddin SM
Am Heart J; 2006 Aug; 152(2):217-22. PubMed ID: 16875900
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
[TBL] [Abstract][Full Text] [Related]
13. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
Katragadda S; Arora RR
Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
15. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
16. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
17. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
[TBL] [Abstract][Full Text] [Related]
18. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Braga MF; Leiter LA
Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
Macfarlane DP; Paterson KR; Fisher M
Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
